Deferasirox and Sunitinib Malate
Determining the interaction of Deferasirox and Sunitinib Malate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Deferasirox may reduce the blood levels and effects of SUNItinib. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4. In healthy volunteers, administration of the CYP450 3A4 probe substrate midazolam in combination with deferasirox resulted in a reduction of midazolam peak concentration by 23% and systemic exposure by 17%. In the clinical setting, this effect may be more pronounced.
MANAGEMENT: Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.
- Skerjanec A, Wang J, Maren K, Rojkjaer L "Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers." J Clin Pharmacol 50 (2010): 205-13
- "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: deferasirox
Brand name: Exjade, Jadenu, Jadenu Sprinkle
Synonyms: n.a.
Generic Name: sunitinib
Brand name: Sutent
Synonyms: Sunitinib, SUNItinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Deferasirox-Sunkist Vitamin C
- Deferasirox-Sunmark 12 Hour Allergy Relief
- Deferasirox-Sunmark Acid Reducer
- Deferasirox-Sunmark Acid Reducer Maximum Strength
- Deferasirox-Sunmark Acid Reducer Ranitidine
- Deferasirox-Sunmark All Day Allergy-D
- Sunitinib Malate-Deferasirox Sprinkle Granules
- Sunitinib Malate-Deferasirox Tablets
- Sunitinib Malate-Deferasirox Tablets For Oral Suspension
- Sunitinib Malate-Deferiprone
- Sunitinib Malate-Deferiprone Oral Solution
- Sunitinib Malate-Deferiprone Tablets